ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-ONLY NON-MUSCLE INVASIVE BLADDER CANCER

Reuters · 20h ago

Please log in to view news